Estonian Competition Authority
Today, the Director General of the Agency of Medicines Kristin Raudsepp and the Director General of the Competition Authority Märt Ots have signed a cooperation agreement which aims to enhance supervision in the sphere of medicines and develop legislation pertaining to the sphere.
First and foremost, the Agency of Medicines and the Competition Authority wish to cooperate for the identification of dominant influence, unfair prices or unequal competitive conditions which may emerge in the medicines market. Within the framework of the agreement, the Agency of Medicines and the Competition Authority will be exchanging information necessary for more effective supervision and will be collaborating on developing and amending legal acts regulating the sphere.
“The objective of the Agency of Medicines is the protection of people’s health, and to do this, we need to be sure of how medicines are produced by companies and what their conditions of sale are. The sector of the development, production, and sales of medicines is one of the most strictly regulated spheres, and supervision also needs to be strict for the sake of people’s safety. This is what we set as our goal by signing the agreement today,” said the Director General of the Agency of Medicines Kristin Raudsepp.
“The Competition Authority has been constantly monitoring the functioning of the medicines market and the business relationships between the companies on the market for years. The cooperation agreement signed today will definitely help to revive supervision in the sector and to achieve synergy in solving problematic situations,” added the Director General of the Competition Authority Märt Ots.
The cooperation agreement has been concluded for an indefinite period.